Candesartan cilexetil: A pharmacoeconomic review of its use in chronic heart failure and hypertension

PharmacoEconomics

Volumn 24, Issue 12, 2006, Pages 1249-1272

  Plosker, Greg L ^a   Keam, Susan J ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KENZEN; LISINOPRIL; LOSARTAN; PLACEBO; VALSARTAN;

ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; HEADACHE; HEALTH CARE COST; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MEDICAL LITERATURE; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CHRONIC DISEASE; COST OF ILLNESS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; TETRAZOLES;

EID: 33845397862     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624120-00008     Document Type: Article

References (87)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005 Sep 20; 112 (12): e154-235
2. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 Jun; 26 (11): 1115-40
3. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006 Jan; 22 (1): 23-45
4. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertension 2003; 21: 1983-92
5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical trials. Third joint task force of European and other societies on cardiovascular disease prevention in clinical trials. Eur J Cardiovasc Prev Rehab 2003 Dec; 10 Suppl. 1: S1-78
6. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertension 2003; 21: 1011-53
7. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. NICE clinical guideline 34 (partial update of NICE clinical guideline 18). 2006 June, London [online]. Available from URL: www.nice.org.uk [Accessed 2006 Sep 4]
8. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004 Mar 13; 328: 634-40
9. Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005 May; 19 (5): 331-9
10. Ruilope LM, Rosei EA, Bakris GL, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005; 14 (4): 196-209
11. Trenkwalder P. Preventing the cardiovascular complications of hypertension. Eur Heart J 2004; 6 Suppl. H: H37-42
12. Cooper ME, Tikellis C, Thomas MC. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. J Hypertens 2006; 24 Suppl. 1: S57-63
13. Hollenberg NK. Diabetes, nephropathy, and the renin system. J Hypertens 2006; 24 Suppl. 1: S81-7
14. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. ASCOT Investigators. Lancet 2005 Sep 10; 366 (9489): 895-906
15. Sjolie AK, Bilous R, Chaturvedi N, et al. The DIabetic REtision nopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005; 6 (1): 25-32
16. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20 (11): 2293-300
17. Ariff B, Zambanini A, Vamadeva S, et al. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006 Aug 3; 37 (9): 2381-4
18. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 Oct 29; 366 (9496): 1545-53
19. Thöne-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens 2006; 24 Suppl. 1: S115-21
20. Fenton C, Scott LJ. Candesartan cilexetil: a review of its use in the management of chronic heart failure. Drugs 2005; 65 (4): 537-58
21. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62 (8): 1253-87
22. AstraZeneca. Atacand®. prescribing information [online]. Available from URL: http://www.atacand.com [Accessed 2006 Jul 4]
23. AstraZeneca. Atacand®. prescribing information [online]. Available from URL: http://www.atacand-us.com/hcp [Accessed 2006 Jul 4]
24. Takeda Pharmaceutical Company Ltd. Prescribing information - Amias®. (candesartan cilexetil) [online]. Available from URL: http://www.takeda.co.uk/ product_information/amias-pil.pdf [Accessed 2006 Jul 4]
25. Takeda. Long-acting angiotensin II receptor antagonist: Blopress®. tablets - candesartan cilexetil tablets (14th version) [online]. Available from URL: http://www.e-search.ne.jp/~jpr/HTML/EJPR002.HTM [Accessed 2006 Aug 18]
26. Lacey L, Tabberer M. Economic burden of post-acute myocardial infarction heart failure in the United Kingdom. Eur J Heart Fail 2005 Jun; 7 (4): 677-83
27. McMurray JJ, Stewart S. Heart failure: epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596-602
28. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 Feb 14; 113 (6): e85-151
29. Khan JM, Beevers DG. Management of hypertension in ethnic minorities. Heart 2005 Aug; 91 (8): 1105-9
30. Amin SP, Mullins CD, Duncan BS, et al. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. Am J Health Syst Pharm 1999 Aug 1; 56: 1515-20
31. Montgomery AA, Fahey T, Ben-Shlomo Y, et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003 Sep; 21 (9): 1753-9
32. Linjer E, Hedner T, Jonsson B, et al. Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Press 2005; 14 (2): 107-13
33. Rodriguez-Roca GC, Alonso-Moreno FJ, Garcia-Jimenez A, et al. Cost-effectiveness of ambulatory blood pressure monitoring in the follow-up of hypertension. Blood Press 2006; 15 (1): 27-36
34. Berto P, Degli Esposti E, Ruffo P, et al. The pandora project: cost of hypertension from a general practitioner database. Blood Press 2002; 11 (3): 151-6
35. Nakamura K, Okamura T, Kanda H, et al. Impact of hypertension on medical economics: a 10-year follow-up study of national health insurance in Shiga, Japan. Hypertens Res 2005 Nov; 28 (11): 859-64
36. Balmori Melian E, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62 (5): 787-816
37. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003 Sep 6; 362: 767-71
38. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The CHARM Investigators and Committees. Lancet 2003 Sep 6; 362: 772-6
39. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 Sep 6; 362: 777-81
40. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The CHARM Investigators and Committees. Lancet 2003 Sep 6; 362: 759-66
41. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results of the CHARM low-left ventricular ejection fraction trials. Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Circulation 2004; 110: 2618-26
42. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. The SCOPE Study Group. J Hypertens 2003 May; 21 (5): 875-86
43. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. The SCOPE Study Group. J Hypertension 2004; 22 (8): 1605-12
44. Zanchetti A, Elmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE): a review. Blood Press 2006; 15 (2): 71-9
45. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003 Aug; 21 (8): 1563-74
46. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998 Jan; 7 (1): 53-9
47. Philipp T, Letzel H, Arens HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997 Sep; 11 Suppl 2: S67-8
48. Farsang C, Kawecka-Jaszcz K, Langan J, et al. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001; 21 (1): 17-23
49. Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1 (2): 52-7
50. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 2000 Oct; 22: 1186-203
51. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000 May; 13 (5 Pt 1): 504-11
52. Imbs JL, Nisse-Durgeat S. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. The French Collaborative Candesartan Study Group. Int J Clin Pract 2005 Jan; 59 (1): 78-84
53. Bakris G, Gradman A, Reif M, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. The CLAIM Study Investigators. J Clin Hypertens 2001; 3 (1): 16-21
54. Lacourcìere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999 Dec; 12 (12 Pt 1-2): 1181-7
55. Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM study II. The CLAIM Study Investigators. J Hum Hypertens 2001; 15 (7): 475-80
56. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. The Effect Study Group. Blood Press 2001; 10 (1): 43-51
57. Kloner RA, Weinberger M, Pool JL, et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am J Cardiol 2001 Mar 15; 87 (6): 727-31
58. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT(1)-receptor blockers: differences in potency and efficacy. Blood Press 2002; 11 (5): 293-301
59. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000 Apr; 13 (Pt 1): 418-26
60. Fogari R, Mugellini A, Zoppi A, et al. A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists, and their activation of the renin-angiotensin system. Curr Ther Res Clin Exp 2000 Oct; 61: 669-79
61. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003 Sep; 21 (9): 1761-9
62. Sever PS, Chang CL. Discordant responses to two classes of drugs acting on the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst 2001 Mar; 2 (1): 25-30
63. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. The CALM Study Group. BMJ 2000 Dec 9; 321 (7274): 1440-4
64. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: The CALM II study. Diabetes Care 2005; 28 (2): 273-7
65. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002 Jun; 15 (6): 544-9
66. Belcher G, Hubner R, George M, et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997 Sep; 11 Suppl 2: S85-9
67. Tanser PH, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. Am J Hypertens 2000 Feb; 13 (2): 214-8
68. McMurray JJ, Andersson FL, Stewart S, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. The CHARM Investigators and Committees. Eur Heart J 2006 Jun; 27 (12): 1447-58
69. Lamotte M, Annemans L, Schockaert B. A cost-effectiveness analysis of candesartan in the treatment of chronic heart failure [abstract no. CV3]. Value Health 2005; 8 (6): A3. Plus oral presentation at ISPOR Eighth Annual European Congress; 2005 Nov 6-8; Florence
70. Willams SA, Stern LS, McMurray JJ, et al. A pharmacoeconomic evaluation of the effects of candesartan on cardiovascular hospitalizations in patients with chronic heart failure [abstract no. P226]. 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; 2006 May 7-9; Washington, D.C. Circulation Electronic Pages [online]; 2006113: e833
71. Voelkl M, Pirk O, Juenger V. Cost-effectiveness of candesartan in Germany for patients with chronic heart failure [abstract no. PCV26]. Value Health 2005; 8 (6): A96
72. Voelkl M, Pirk O, Juenger V. Case-based-costing vs. Markov-modelling: a comparison of cost-effectiveness-analyses for candesartan in patients with chronic heart failure [abstract no. PCV22]. Value Health 2005; 8 (6): A95
73. Lundkvist J, Ekman M, Kartman B, et al. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. J Hum Hypertens 2005; 19: 569-76
74. Lindholm LH, Kartman B, Carlberg B, et al. Cost implications of development of diabetes in the ALPINE study. J Hypertens 2006; 24 Suppl. 1: S65-72
75. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The ALLHAT Officers and Coordinators for the ALLHAT Collaborate Research. JAMA 2000; 283: 1967-75
76. Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developers' handbook: methodology checklist 2. Randomised controlled trials [online]. Available from URL: http://www.sign.ac.uk/methodology/checklists.html [Accessed 2006 Oct 24]
77. Joint Formulary Committee. British National Formulary. 52nd ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006 [online]. Available from URL: http://www.bnf.org [Accessed 2006 Oct 24]
78. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163 (14): 1637-41
79. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
80. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). CIBIS-II Investigators and Health Economics Group. Eur Heart J 2001; 22: 1021-31
81. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail 1995; 1: 371-80
82. Glick HA, Orzol SM, Tooley JF, et al. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002; 16: 53-9
83. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143-9
84. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. The National High Blood Pressure Education Program Coordinating Committee. JAMA 2003 May 21; 289 (19): 2560-72
85. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhigitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002 Dec 18; 288 (23): 2981-97
86. Blood Pressure Association. Medicines for high blood pressure. The new UK guidelines and what they mean for you [online]. Available from URL: www.bpassoc.org.uk [Accessed 2006 Sep 4]
87. McInnes G, Burke TA, Carides G. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the losartan intervention for endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2006 Jan; 20 (1): 51-8